TENGJUN BIOTECHNOLOGY CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2 USD | -33.33% |
|
-.--% | -66.67% |
| 2023 | Tengjun Biotechnology Corp. Announces Chief Executive Officer Changes | CI |
| 2023 | Tengjun Biotechnology Corp. Announces Chief Financial Officer Changes | CI |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 148.7 | 95.34 | 539.2 | 2,518 | 195.9 | 385.2 |
| Enterprise Value (EV) 1 | 148.9 | 95.58 | 539.5 | 2,518 | 195.6 | 382.4 |
| P/E ratio | -3,054 x | -1,995 x | -8,328 x | -46,064 x | -81.4 x | 28.3 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 2,565,905 x |
| EV / Revenue | - | - | - | - | - | 2,547,052 x |
| EV / EBITDA | - | - | - | - | -466,048,274 x | 23,355,861 x |
| EV / FCF | -5,613 x | -2,865 x | -14,304 x | -75,955 x | 94.9 x | -67 x |
| FCF Yield | -0.02% | -0.03% | -0.01% | -0% | 1.05% | -1.49% |
| Price to Book | -691 x | -389 x | -1,928 x | -8,914 x | -89.4 x | 26.7 x |
| Nbr of stocks (in thousands) | 38,137 | 38,137 | 43,137 | 45,783 | 65,309 | 96,309 |
| Reference price 2 | 3.900 | 2.500 | 12.50 | 55.00 | 3.000 | 4.000 |
| Announcement Date | 3/7/18 | 3/8/19 | 2/28/20 | 2/17/21 | 3/31/22 | 4/17/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | 150.1 |
| EBITDA | - | - | - | - | -0.4198 | 16.37 |
| EBIT 1 | -0.0325 | -0.0299 | -0.0395 | -0.0323 | -0.7382 | 16.06 |
| Operating Margin | - | - | - | - | - | 10.7% |
| Earnings before Tax (EBT) 1 | -0.0482 | -0.0478 | -0.0599 | -0.0539 | -0.7475 | 15.28 |
| Net income 1 | -0.0482 | -0.0478 | -0.0599 | -0.0539 | -0.7475 | 11.35 |
| Net margin | - | - | - | - | - | 7.56% |
| EPS 2 | -0.001277 | -0.001253 | -0.001501 | -0.001194 | -0.0368 | 0.1415 |
| Free Cash Flow 1 | -0.0265 | -0.0334 | -0.0377 | -0.0332 | 2.062 | -5.712 |
| FCF margin | - | - | - | - | - | -3.8% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/7/18 | 3/8/19 | 2/28/20 | 2/17/21 | 3/31/22 | 4/17/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.2 | 0.24 | 0.27 | 0.28 | - | - |
| Net Cash position 1 | - | - | - | - | 0.29 | 2.83 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -0.03 | -0.03 | -0.04 | -0.03 | 2.06 | -5.71 |
| ROE (net income / shareholders' equity) | 23.1% | 20.8% | 22.8% | 19.2% | 43.2% | 189% |
| ROA (Net income/ Total Assets) | -527% | -510% | -595% | -277% | -3.41% | 27.6% |
| Assets 1 | 0.009145 | 0.009379 | 0.0101 | 0.0194 | 21.92 | 41.06 |
| Book Value Per Share 2 | -0.0100 | -0.0100 | -0.0100 | -0.0100 | -0.0300 | 0.1500 |
| Cash Flow per Share | - | - | - | 0 | 0 | 0.0300 |
| Capex | - | - | - | - | 0.31 | 0.01 |
| Capex / Sales | - | - | - | - | - | 0% |
| Announcement Date | 3/7/18 | 3/8/19 | 2/28/20 | 2/17/21 | 3/31/22 | 4/17/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -66.67% | 201M | |
| +25.15% | 64.64B | |
| +35.00% | 34.08B | |
| +24.76% | 8.88B | |
| -0.27% | 6.71B | |
| +9.90% | 6.41B | |
| +2.16% | 5.05B | |
| +7.62% | 4.57B | |
| -10.25% | 3.23B | |
| +3.51% | 2.5B |
- Stock Market
- Equities
- TJBH Stock
- Financials Tengjun Biotechnology Corp.
